Mesoblast, JCR Expand the Use of Mesenchymal Stem Cells for Treating Newborns with HIE
News
Mesoblast announced it has expanded its partnership with JCR Pharmaceuticals in Japan to include the use of mesenchymal stem cells (MSCs) for treating newborns who have neonatal hypoxic ischemic encephalopathy (HIE), a ... Read more